Atara Biotherapeutics, Inc. 8-K

What Happened
Atara Biotherapeutics (NASDAQ: ATRA) announced on May 1, 2026 that it received a Nasdaq Listing Qualifications notice on April 30, 2026 stating the company no longer meets Nasdaq’s $50 million minimum market value for listed securities (MVLS) requirement under Listing Rule 5450(b)(2)(A). Nasdaq has provided a 180‑day compliance period under Rule 5810(c)(3)(C), giving the company until October 27, 2026 to regain compliance. The notice does not affect current trading; ATRA will continue to trade on the Nasdaq Global Select Market.

Key Details

• Notice received April 30, 2026; compliance deadline is October 27, 2026 (180 days).
• MVLS threshold cited: $50 million; regaining compliance requires MVLS ≥ $50M for at least 10 consecutive business days (Nasdaq may require up to ~20 business days).
• Shares continue trading on Nasdaq Global Select Market under ticker ATRA; failure to regain compliance could lead to delisting and a possible appeal to a Nasdaq Hearings Panel.
• Company may consider options (including transfer to The Nasdaq Capital Market) but made no commitment to any specific action; report signed by President & CEO Dr. AnhCo Thieu Nguyen.

Why It Matters
This filing signals a material listing risk: if Atara does not restore its market value by the deadline, Nasdaq could begin delisting procedures, which can reduce liquidity and investor accessibility. For now, the stock remains listed and tradable, but investors should monitor the company’s market value, subsequent disclosures, and any corporate actions the company pursues to regain compliance.